Major Complications, Mortality, and Resource Utilization After Open Abdominal Surgery: 0.9% Saline Compared to Plasma-Lyte
Overview
Authors
Affiliations
Objective: To assess the association of 0.9% saline use versus a calcium-free physiologically balanced crystalloid solution with major morbidity and clinical resource use after abdominal surgery.
Background: 0.9% saline, which results in a hyperchloremic acidosis after infusion, is frequently used to replace volume losses after major surgery.
Methods: An observational study using the Premier Perspective Comparative Database was performed to evaluate adult patients undergoing major open abdominal surgery who received either 0.9% saline (30,994 patients) or a balanced crystalloid solution (926 patients) on the day of surgery. The primary outcome was major morbidity and secondary outcomes included minor complications and acidosis-related interventions. Outcomes were evaluated using multivariable logistic regression and propensity scoring models.
Results: For the entire cohort, the in-hospital mortality was 5.6% in the saline group and 2.9% in the balanced group (P < 0.001). One or more major complications occurred in 33.7% of the saline group and 23% of the balanced group (P < 0.001). In the 3:1 propensity-matched sample, treatment with balanced fluid was associated with fewer complications (odds ratio 0.79; 95% confidence interval 0.66-0.97). Postoperative infection (P = 0.006), renal failure requiring dialysis (P < 0.001), blood transfusion (P < 0.001), electrolyte disturbance (P = 0.046), acidosis investigation (P < 0.001), and intervention (P = 0.02) were all more frequent in patients receiving 0.9% saline.
Conclusions: Among hospitals in the Premier Perspective Database, the use of a calcium-free balanced crystalloid for replacement of fluid losses on the day of major surgery was associated with less postoperative morbidity than 0.9% saline.
Ramanan M, Hammond N, Billot L, Delaney A, Devaux A, Finfer S Intensive Care Med. 2025; 51(2):249-258.
PMID: 39928118 DOI: 10.1007/s00134-024-07764-2.
Mhanna A, Beran A, Srour O, Mhanna M, Assaly A, Elsayed A Proc (Bayl Univ Med Cent). 2024; 37(2):295-302.
PMID: 38343480 PMC: 10857664. DOI: 10.1080/08998280.2024.2301904.
Duan G, Deng H, Fu H, Wang L, Yang H Int J Gen Med. 2023; 16:5855-5868.
PMID: 38111852 PMC: 10725832. DOI: 10.2147/IJGM.S427904.
Revisiting the Use of Normal Saline for Peritoneal Washing in Ovarian Cancer.
Akasaka H, Naora H Int J Mol Sci. 2023; 24(22).
PMID: 38003636 PMC: 10671679. DOI: 10.3390/ijms242216449.
Chen Y, Gao Y Ther Clin Risk Manag. 2023; 19:783-799.
PMID: 37850070 PMC: 10577264. DOI: 10.2147/TCRM.S416785.